Lilly’s Donanemab Slows Cognitive Decline; FDA Filing Imminent
Full Approval Sought After Accelerated Nod Denied Previously
The company’s anti-amyloid antibody succeeded in Phase III with efficacy at least on par with Eisai/Biogen’s Leqembi, but with ARIA-related deaths unseen with the rival therapy.
